ID | Gender | Age (years) | Ethnicity | Disease duration (years) | Clinical SELENA-SLEDAI | BILAG- 2004 | Anti-dsDNA (IU/mL)* | Autoantibodies | Treatment naive | Treatment at visit | Disease activity state† | Biological phenotype | |||
HCQ | Prednisone (mg/kg/day) | NSAIDs | DMARD/biologicals | ||||||||||||
Pt1 | Female | 15.7 | White | 1.2 | 12 | 21 | 380 | Anti-RNP, anti-Sm | No | Yes | 0.12 | No | Mycophenolate mofetil | Flare | HBP |
Pt1 | Female | 17.6 | White | 3.2 | 0 | 1 | 53 | Anti-RNP, anti-Sm | No | Yes | – | No | Mycophenolate mofetil/belimumab | LLDAS | MBP |
Pt1 | Female | 14.5 | White | 0 | 10 | 19 | 548 | Anti-RNP, anti-Sm | Yes | No | – | No | No | At diagnosis | LBP |
Pt2 | Female | 17.9 | White | 3 | 12 | 12 | 24 | Anti-SSA, anti-Sm | No | Yes | 0.66 | No | Mycophenolate mofetil | Flare | MBP |
Pt2 | Female | 19 | White | 4.1 | 0 | 0 | 33 | Anti-SSA, anti-Sm | No | Yes | – | No | Mycophenolate mofetil | LLDAS | LBP |
Pt3 | Female | 9.7 | Mixed | 1.3 | 14 | 22 | 479 | – | No | Yes | 0.26 | No | Mycophenolate mofetil | Flare | MBP |
Pt3 | Female | 12.5 | Mixed | 4.1 | 0 | 0 | 46 | – | No | Yes | 0.05 | No | Mycophenolate mofetil | LLDAS | LBP |
Pt4 | Female | 18.5 | White | 2.8 | 2 | 12 | 0.4 | Anti-SSA/B | No | Yes | 0.15 | Yes | Mycophenolate mofetil | Flare | MBP |
Pt4 | Female | 17.7 | White | 1.9 | 2 | 2 | 1.5 | Anti-SSA/B | No | Yes | 0.08 | Yes | Mycophenolate mofetil/belimumab | LLDAS | MBP |
Pt5 | Female | 17.7 | White | 3.4 | 3 | 20 | 7.1 | – | No | Yes | – | No | Mycophenolate mofetil | Flare | MBP |
Pt5 | Female | 18 | White | 3.7 | 0 | 0 | 3.8 | – | No | Yes | 0.06 | No | Mycophenolate mofetil | LLDAS | MBP |
Pt6 | Female | 15.4 | White | 3.2 | 0 | 0 | 11 | Anti-RNP | No | Yes | – | No | Mycophenolate mofetil | LLDAS | LBP |
Pt7 | Female | 15 | African-American | 6 | 6 | 28 | 113 | Anti-RNP | No | Yes | – | No | Mycophenolate mofetil | Flare | HBP |
Pt8 | Female | 15.9 | Mixed | 0 | 6 | 22 | 32 | Anti-RNP | No | No | 0.33 | No | No | At diagnosis | MBP |
Pt9 | Male | 18.5 | South-Asian | 3.1 | 0 | 0 | 1.1 | – | No | Yes | – | No | Mycophenolate mofetil | LLDAS | LBP |
Pt10 | Female | 5.5 | White | 0.8 | 0 | 0 | 0.5 | Anti-SSA | No | Yes | – | No | No | LLDAS | LBP |
Pt11 | Female | 9.8 | African-American | 0 | 10 | 29 | 354 | Anti-SSA | Yes | No | – | No | No | At diagnosis | HBP |
Pt12 | Female | 14.5 | Mixed | 0 | 6 | 13 | 11 | Anti-SSA/B, anti-RNP, anti-Sm | Yes | No | – | No | No | At diagnosis | LBP |
Pt13 | Female | 11.8 | Hispanic | 0 | 4 | 21 | 211 | Anti-RNP, anti-Sm | Yes | No | – | No | No | At diagnosis | HBP |
Pt14 | Female | 14.2 | White | 0 | 2 | 8 | 1.1 | Anti-RNP | Yes | No | – | No | No | At diagnosis | LBP |
Pt15 | Female | 16.6 | Asian | 0 | 14 | 64 | 33 | Anti-SSA/B, anti-RNP, anti-Sm | No | No | 0.99 | No | No | At diagnosis | MBP |
Pt16 | Female | 17.1 | White | 0 | 5 | 13 | 2.9 | Anti-RNP | Yes | No | – | No | No | At diagnosis | MBP |
Pt17 | Female | 10.3 | African-American | 0 | 15 | 36 | 35 | Anti-SSA/B | Yes | No | – | No | No | At diagnosis | HBP |
Mixed ethnicity: pt3 (Hispanic-White), pt8 (African-American-Hispanic), pt12 (African-American-White).
*Measured with a fluorometric enzyme immunoassay, cut-off is 10 IU/mL.
†At diagnosis refers to patients sampled within 2 weeks from diagnosis.
BILAG, British Isles Lupus Assessment Group; DMARD, disease-modifying antirheumatic drug; HBP, high biological phenotype; HCQ, hydroxychloroquine; LBP, low biological phenotype; LLDAS, Low Lupus Disease Activity State; MBP, mixed biological phenotype; NSAIDs, non-steroidal anti-inflammatory drugs; SELENA-SLEDAI, Safety of Estrogens in Systemic Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus Disease Activity Index.